$75.16+26.74% · 3M
Moving avg
1W-16.70%
1M-3.34%
3M+32.01%
6M+96.74%
YTD+139.35%
1Y+188.06%
3Y+970.58%
5Y+2779.50%
52-week range
$14.4289% of range$82.96
Company health
Value0/6
Growth3/6
Profitability2/6
Health1/6
Dividend0/6
Bull vs bear
Strengths
- Analyst consensus is "Buy"
- High return on equity (4682%)
- Revenue compounding 32% a year
Risks
- Richly valued at 322.4x earnings
- Currently unprofitable
- Burning free cash flow
- Highly leveraged (debt is 4.4x equity)
Key statistics
Valuation
Market cap
$6.68B
Enterprise value
$6.82B
P/E ratio (TTM)
322.38x
P/S ratio (TTM)
23.80x
EV/EBITDA
126.71x
Per share & returns
EPS (TTM)
$0.25
Dividend yield
0.00%
Beta (1Y)
0.55
30-day change
-3.34%
Trading
Volume (24h)
1.22M
Previous close
$78.79
Shares outstanding
88.93M
About Liquidia Corporation
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Exchange
NASDAQ
Symbol
LQDA
Liquidia Corporation is a mid-cap healthcare company in the Medical - Pharmaceuticals industry. Its shares are listed on NASDAQ (United States) and trade under the ticker LQDA.
Frequently asked questions
What is Liquidia Corporation's market cap?
Liquidia Corporation (LQDA) has a market capitalization of $6.68B.
What is Liquidia Corporation's P/E ratio?
Liquidia Corporation trades at a price-to-earnings (P/E) ratio of 322.38.
What exchange does LQDA trade on?
LQDA trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,220.72+0.04%
$1.15T cap
Johnson & JohnsonJNJ
$261.31+0.17%
$629.74B cap
AbbVie Inc.ABBV
$250.53+0.71%
$442.63B cap
UnitedHealth Group IncorporatedUNH
$402.71-0.71%
$365.71B cap
Roche Holding AGSWX: ROP
CHF 362.30-0.88%
$355.30B cap
Merck & Co., Inc.MRK
$134.73+1.36%
$332.76B cap
Novartis AGSWX: NOVN
CHF 123.96-0.19%
$290.28B cap
AstraZeneca PLCLON: AZN
£117.08+0.05%
$245.27B cap